Dermatomyositis is a rare autoimmune disease causing muscle weakness and skin rashes. It accounts for approximately 1.2 to 21 cases per 100,000 people, with incidence estimates ranging from 1.0 to 15 per million. The demand for better therapies is rising due to limited treatment options. There is a growing focus on advanced dermatomyositis therapeutics, including biologics and immunomodulators. Recent developments, such as novel drug candidates targeting inflammatory pathways, are driving market growth. With increasing research and clinical trials, the dermatomyositis drug pipeline is expected to expand significantly in the coming years, improving patient outcomes and treatment efficacy.
Major companies involved in the dermatomyositis pipeline drugs market include AstraZeneca, Pfizer, and others.
Leading drugs currently in the pipeline include Brepocitinib, M5049 High Dose, and others.
Increased research funding, advancements in immunomodulatory therapies, and a rising number of clinical trials on biologics and targeted treatments are driving the growth of the dermatomyositis drug pipeline.
The Dermatomyositis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into dermatomyositis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dermatomyositis. The dermatomyositis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dermatomyositis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with dermatomyositis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dermatomyositis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Dermatomyositis is a rare inflammatory disease affecting the muscles and skin. It occurs due to an abnormal immune response, leading to muscle weakness and a distinctive skin rash. The exact cause is unknown but may involve genetic, environmental, or autoimmune factors. It can affect individuals of any age, with symptoms ranging from fatigue to difficulty swallowing.
Dermatomyositis treatments focus on reducing inflammation and managing symptoms. Common therapies include corticosteroids, immunosuppressive drugs, and intravenous immunoglobulin (IVIG). Physical therapy helps maintain muscle strength. Emerging treatments, such as biologics and targeted immunotherapies, aim to improve outcomes and reduce disease progression.
The dermatomyositis drug pipeline is expanding due to rising disease incidence and ongoing clinical research. Current dermatomyositis incidence estimates range from 1.0 to 15 per million, with prevalence ranging from 1.2 to 21 per 100,000. In the United States, approximately 2,858 new dermatomyositis cases occur annually, with a higher incidence among females. Juvenile dermatomyositis affects 500-1,000 children in the United Kingdom and Ireland.
This section of the report covers the analysis of dermatomyositis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total dermatomyositis clinical trials.
The drug molecule categories covered under the dermatomyositis pipeline analysis include small molecules, biologics, gene therapy, cell-based therapies, and nucleic acid therapies. The dermatomyositis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dermatomyositis.
The EMR report for the dermatomyositis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dermatomyositis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Dermatomyositis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for dermatomyositis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of dermatomyositis drug candidates.
Brepocitinib is a dual selective TYK2/JAK1 inhibitor administered orally once daily. The drug candidate is undergoing a Phase III, randomized, placebo-controlled clinical trial, which is sponsored by Priovant Therapeutics, Inc. The study aims to evaluate the efficacy and safety of brepocitinib in adults with dermatomyositis. It measures differences in the total improvement score (TIS) over 52 weeks, followed by an optional 52-week open-label extension phase.
M5049, developed by EMD Serono Research & Development Institute, Inc., is an orally administered small molecule dual TLR7 and TLR8 antagonist targeting immune system dysfunction. It is a part of a Phase II study (NEPTUNIA) that aims to evaluate the efficacy and safety of Enpatoran in 40 participants with dermatomyositis (DM) and polymyositis (PM) over 24 weeks. The study is estimated to be completed by April 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Dermatomyositis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for dermatomyositis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into dermatomyositis collaborations, regulatory environments, and potential growth opportunities.
Global Skin Care Products Market Report and Forecast
Global Skincare Devices Market Report and Forecast
United Kingdom Professional Skincare Product Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share